Assessment of Change in Atherosclerotic Plaque by Serial CCTA

Yonsei University400 enrolled

Overview

Assessment of Change in AtheROSclerotic Plaque by Serial CCTA (ACROSS) is designed as a prospective observational study which aim is to demonstrate the effect of statins on coronary atherosclerosis, assessed by quantitative analysis of CCTA.

Study Type

OBSERVATIONAL

Enrollment

400

Conditions

Coronary Artery Disease Hydroxymethylglutaryl-CoA Reductase Inhibitors Coronary Arteriosclerosis

Interventions

AtorvastatinDRUG

Patients diagnosed with coronary artery disease by CCTA be enrolled. Among enrolled patients, patients who is indicated to statin treatment according to the current ACC/AHA guideline will be treated with atorvastatin.

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who underwent clinically indicated CCTA (index CCTA) * Mild to moderate stenosis (25-69%) on CCTA * ≥1 clinical risk factors (Smoking, HTN, HDL\<40, Premature FHx, M ≥45, F ≥55) for CAD Exclusion Criteria: * Acute coronary syndrome (unstable angina or MI) * Positive (not equivocal) stress test * Contraindications to statin

Locations (1)

Severance Cardiovascular Hospital, Yonsei University College of Medicine

Seoul, South Korea

RECRUITING

Outcomes

Primary Outcomes

Difference in percent change of total atheroma volume assessed by CCTA between statin-taking and statin-naïve group

Patients indicated with statin therapy according to current guideline will receive atorvastatin.

Time frame: 24 months

Secondary Outcomes

Change of total atheroma volume at 24 months compared with baseline total atheroma volume

total atheroma volume assessed by CCTA

Time frame: 24 months

Central Contacts

Hyuk-Jae Chang, MD, PhD

CONTACT

+82-2-2228-8454 hjchang@yuhs.ac

Sang-Eun Lee, MD, PhD

CONTACT

tkddmss@yuhs.ac

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.